Mesoporous silica nanoparticle based enzyme responsive system for colon specific drug delivery through guar gum capping

Colloids and Surfaces B: Biointerfaces

Volumn 150, Issue , 2017, Pages 352-361

  Kumar, Balmiki ^a   Kulanthaivel, Senthilguru ^a   Mondal, Animesh ^a   Mishra, Smruti ^a   Banerjee, Biplab ^b   Bhaumik, Asim ^b   Banerjee, Indranil ^a   Giri, Supratim ^a  

^a NATIONAL INSTITUTE OF TECHNOLOGY   (India)

^b DEPARTMENT OF MATERIALS SCIENCE   (India)

Author keywords

Colon targeted delivery; Controlled release; Enzyme responsive materials; Mesoporous silica nanomaterials; Oral administration

Indexed keywords

BIODEGRADATION; CELL CULTURE; CHARACTERIZATION; DIGESTIVE SYSTEM; ENZYMES; NANOPARTICLES; NANOSTRUCTURED MATERIALS; SILICA; THERMOGRAVIMETRIC ANALYSIS;

CONTROLLED RELEASE; ENZYME RESPONSIVE MATERIALS; MESOPOROUS SILICA; ORAL ADMINISTRATION; TARGETED DELIVERY;

MESOPOROUS MATERIALS;

FLUOROURACIL; GUAR GUM; MESOPOROUS SILICA NANOPARTICLE; NITROGEN; ANTINEOPLASTIC AGENT; GALACTAN; MANNAN; METAL NANOPARTICLE; PLANT GUM; POLYMER; SILICON DIOXIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCHEMICAL ANALYSIS; CANCER CELL LINE; COLON; COLON CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; ELECTRON MICROSCOPY; ENZYME DEGRADATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; MICROENVIRONMENT; MOLECULAR INTERACTION; NANOANALYSIS; NANOFABRICATION; NONHUMAN; PARTICLE SIZE; SIMULATION; SYNTHESIS; THERMOGRAVIMETRY; X RAY POWDER DIFFRACTION; ADSORPTION; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; GASTROINTESTINAL TRACT; METABOLISM; ORAL DRUG ADMINISTRATION; TEMPERATURE; TUMOR CELL LINE; X RAY DIFFRACTION;

ADMINISTRATION, ORAL; ADSORPTION; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLON; DRUG DELIVERY SYSTEMS; FLOW CYTOMETRY; FLUOROURACIL; GALACTANS; GASTROINTESTINAL TRACT; HUMANS; MANNANS; METAL NANOPARTICLES; MICROSCOPY, ELECTRON; NITROGEN; PLANT GUMS; POLYMERS; SILICON DIOXIDE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TEMPERATURE; THERMOGRAVIMETRY; X-RAY DIFFRACTION;

EID: 85006804580     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2016.10.049     Document Type: Article

References (68)

1. [1] Simmonds, P.C., Primrose, J.N., Colquitt, J.L., Garden, O.J., Poston, G.J., Rees, M., Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br. J. Cancer 94 (2006), 982–999.
2. [2] Pin, A.-L., Houle, F., Huot, J., Recent advances in colorectal cancer research: the microenvironment impact. Cancer Microenviron. 4 (2011), 127–131.
3. [3] Maksimenko, A., Alami, M., Zouhiri, F., Brion, J.-D., Pruvost, A., Mougin, J., Hamze, A., Boissenot, T., Provot, O., Desmaele, D., Couvreur, P., Therapeutic modalities of squalenoyl nanocomposites in colon cancer: an ongoing search for improved efficacy. ACS Nano 8 (2014), 2018–2032.
4. [4] Renehan, A.G., Egger, M., Saunders, M.P., O'Dwyer, S.T., Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. Br. Med. J. 324 (2002), 1–8.
5. [5] Nelson, J.L., Roeder, B.L., Carmen, J.C., Roloff, F., Pitt, W.G., Ultrasonically activated chemotherapeutic drug delivery in a rat model. Cancer Res. 62 (2002), 7280–7283.
6. [6] Dawson, L.A., Sharpe, M.B., Image-guided radiotherapy: rationale, benefits, and limitations. Lancet Oncol. 7 (2006), 848–858.
7. [7] Plevova, P., Prevention and treatment of chemotherapy- and radiotherapy-induced oral mucositis: a review. Oral Oncol. 35 (1999), 453–470.
8. [8] Friend, D.R., Colon-specific drug delivery. Adv. Drug Deliv. Rev. 7 (1991), 149–199.
9. [9] Krishnaiah, Y.S., Khan, M.A., Strategies of targeting oral drug delivery systems to the colon and their potential use for the treatment of colorectal cancer. Pharm. Dev. Technol. 17 (2012), 521–540.
10. [10] Meropol, N.J., Oral fluoropyrimidines in the treatment of colorectal cancer. Eur. J. Cancer 34 (1998), 1509–1513.
11. [11] Sharma, S., Saltz, L.B., Oral chemotherapeutic agents for colorectal cancer. Oncologist 5 (2000), 99–107.
12. [12] Park, J.H., Saravanakumar, G., Kim, K., Kwon, I.C., Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv. Drug Deliv. Rev. 62 (2010), 28–41.
13. [13] Tannergren, C., Bergendal, A., Lennerna, H., Abrahamsson, B., Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment. Mol. Pharm. 6 (2009), 60–73.
14. [14] Prajakta, D., Ratnesh, J., Chandan, K., Suresh, S., Grace, S., Meera, V., Vandana, P., Curcumin loaded pH-sensitive nanoparticles for the treatment of colon cancer. J. Biomed. Nanotechnol. 5 (2009), 445–455.
15. [15] Cerchiara, T., Abruzzo, A., di Cagno, M., Bigucci, F., Bauer-Brandl, A., Parolin, C., Vitali, B., Gallucci, M.C., Luppi, B., Chitosan based micro- and nanoparticles for colon-targeted delivery of vancomycin prepared by alternative processing methods. Eur. J. Pharm. Biopharm. 92 (2015), 112–119.
16. [16] Chaturvedi, K., Kulkarni, A.R., Aminabhavi, T.M., Blend microspheres of poly(3-hydroxybutyrate) and cellulose acetate phthalate for colon delivery of 5-fluorouracil. Ind. Eng. Chem. Res. 50 (2011), 10414–10423.
17. [17] Ahmad, M.Z., Akhter, S., Anwar, M., Ahmad, F.J., Assam bora rice starch based biocompatible mucoadhesive microsphere for targeted delivery of 5-fluorouracil in colorectal cancer. Mol. Pharm. 9 (2012), 2986–2994.
18. [18] Agarwal, T., Narayana, S.N., Pal, K., Pramanik, K., Giri, S., Banerjee, I., Calcium alginate-carboxymethyl cellulose beads for colon-targeted drug delivery. Int. J. Biol. Macromol. 75 (2015), 409–417.
19. [19] Krishnaiah, Y.S.R., Satyanarayana, V., Kumar, B.D., Karthikeyan, R.S., In vitro drug release studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil. Eur. J. Pharm. Sci. 16 (2002), 185–192.
20. [20] Madan, J., Gundala, S.R., Baruah, B., Nagaraju, M., Yates, C., Turner, T., Rangari, V., Hamelberg, D., Reid, M.D., Aneja, R., Cyclodextrin complexes of reduced bromonoscapine in guar gum microspheres enhance colonic drug delivery. Mol. Pharm. 11 (2014), 4339–4349.
21. [21] Das, A., Wadhwa, S., Srivastava, A.K., Cross-linked guar gum hydrogel discs for colon-specific delivery of ibuprofen: formulation and in vitro evaluation. Drug. Deliv. 13 (2006), 139–142.
22. [22] Casadei, M.A., Pitarresi, G., Calabrese, R., Paolicelli, P., Giammona, G., Biodegradable and pH-sensitive hydrogels for potential colon-specific drug delivery: characterization and in vitro release studies. Biomacromolecules 9 (2008), 43–49.
23. [23] Chourasia, M.K., Jain, S.K., Potential of guar gum microspheres for target specific drug release to colon. J. Drug Target. 12 (2004), 435–442.
24. [24] Lee, C.C., Gillies, E.R., Fox, M.E., Guillaudeu, S.J., Frechet, J.M., Dy, E.E., Szoka, F.C., A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc. Natl. Acad. Sci. 103 (2006), 16649–16654.
25. [25] Huang, W., Wang, X., Shi, C., Guo, D., Xu, G., Wang, L., Bodman, A., Luo, J., Fine-tuning vitamin E-containing telodendrimers for efficient delivery of gambogic acid in colon cancer treatment. Mol. Pharm. 12 (2015), 1216–1229.
26. [26] Gao, X., Zheng, F., Guo, G., Liu, X., Fan, R., Qian, Z.-Y., Huang, N., Wei, Y.-Q., Improving the anti-colon cancer activity of curcumin with biodegradable nano-micelles. J. Mater. Chem. B 1 (2013), 5778–5790.
27. [27] Vong, L.B., Yoshitomi, T., Matsui, H., Nagasaki, Y., Development of an oral nanotherapeutics using redox nanoparticles for treatment of colitis-associated colon cancer. Biomaterials 55 (2015), 54–63.
28. [28] Vong, L.B., Nagasaki, Y., Combination treatment of murine colon cancer with doxorubicin and redox nanoparticles. Mol. Pharm. 13 (2016), 449–455.
29. [29] Vong, L.B., Mo, J., Abrahamsson, B., Nagasaki, Y., Specific accumulation of orally administered redox nanotherapeutics in the inflamed colon reducing inflammation with dose–response efficacy. J. Control. Release 210 (2015), 19–25.
30. [30] Lu, J., Liong, M., Li, Z., Zink, J.I., Tamanoi, F., Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small 6 (2010), 1794–1805.
31. [31] Slowing, I.I., Vivero-Escoto, J.L., Wu, C.W., Lin, V.S.-Y., Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv. Drug Deliv. Rev. 60 (2008), 1278–1288.
32. [32] He, Q., Shi, J., Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharmacokinetics and biocompatibility. J. Mater. Chem. 21 (2011), 5845–5855.
33. [33] Giri, S., Trewyn, B.G., Lin, V.S.-Y., Mesoporous silica nanomaterial-based biotechnological and biomedical delivery systems. Nanomedicine (London) 2 (2007), 99–111.
34. [34] Giri, S., Trewyn, B.G., Stellmaker, M.P., Lin, V.S.-Y., Stimuli-responsive controlled-release delivery system based on mesoporous silica nanorods capped with magnetic nanoparticles. Angew. Chem. 44 (2005), 5038–5044.
35. [35] Lai, C.-Y., Trewyn, B.G., Jeftinija, D.M., Jeftinija, K., Xu, S., Jeftinija, S., Lin, V.S.-Y., A mesoporous silica nanosphere-based carrier system with chemically removable CdS nanoparticle caps for stimuli-Responsive controlled release of neurotransmitters and drug molecules. J. Am. Chem. Soc. 125 (2003), 4451–4459.
36. [36] Radu, D.R., Lai, C.-Y., Jeftinija, K., Rowe, E.W., Jeftinija, S., Lin, V.S.-Y., A polyamidoamine dendrimer-capped mesoporous silica nanosphere-based gene transfection reagent. J. Am. Chem. Soc. 2004 (2004), 13216–13217.
37. [37] Zou, Z., He, D., He, X., Wang, K., Yang, X., Qing, Z., Zhou, Q., Natural gelatin capped mesoporous silica nanoparticles for intracellular acid-triggered drug delivery. Langmuir: ACS J. Surf. Colloids 29 (2013), 12804–12810.
38. [38] Zhang, P., Wu, T., Kong, J.L., In situ monitoring of intracellular controlled drug release from mesoporous silica nanoparticles coated with pH-responsive charge-reversal polymer. ACS Appl. Mater. Interfaces 6 (2014), 17446–17453.
39. [39] Chang, B., Chen, D., Wang, Y., Chen, Y., Jiao, Y., Sha, X., Yang, W., Bioresponsive controlled drug release based on mesoporous silica nanoparticles coated with reductively sheddable polymer shell. Chem. Mater. 25 (2013), 574–585.
40. [40] Chen, Z., Li, Z., Lin, Y., Yin, M., Ren, J., Qu, X., Bioresponsive hyaluronic acid-capped mesoporous silica nanoparticles for targeted drug delivery. Chem. Eur. J. 19 (2013), 1778–1783.
41. [41] Li, Z.-Y., Hu, J.-J., Xu, Q., Chen, S., Jia, H.-Z., Sun, Y.-X., Zhuo, R.-X., Zhang, X.-Z., A redox-responsive drug delivery system based on RGD containing peptide-capped mesoporous silica nanoparticles. J. Mater. Chem. B 3 (2015), 39–44.
42. [42] Thornton, P.D., Heise, A., Highly specific dual enzyme-mediated payload release from peptide-coated silica particles. J. Am. Chem. Soc. 132 (2010), 2024–2028.
43. [43] Han, N., Zhao, Q., Wan, L., Wang, Y., Gao, Y., Wang, P., Wang, Z., Zhang, J., Jiang, T., Wang, S., Hybrid lipid-capped mesoporous silica for stimuli-responsive drug release and overcoming multidrug resistance. ACS Appl. Mater. Interfaces 7 (2015), 3342–3351.
44. [44] Singh, N., Karambelkar, A., Gu, L., Lin, K., Miller, J.S., Chen, C.S., Sailor, M.J., Bhatia, S.N., Bioresponsive mesoporous silica nanoparticles for triggered drug release. J. Am. Chem. Soc. 133 (2011), 19582–19585.
45. [45] Liu, J., Zhang, B., Luo, Z., Ding, X., Li, J., Dai, L., Zhou, J., Zhao, X., Ye, J., Cai, K., Enzyme responsive mesoporous silica nanoparticles for targeted tumor therapy in vitro and in vivo. Nanoscale 7 (2015), 3614–3626.
46. [46] Patel, K., Angelos, S., Dichtel, W.R., Coskun, A., Yang, Y.-W., Zink, J.I., Stoddart, J.F., Enzyme-responsive snap-top covered silica nanocontainers. J. Am. Chem. Soc. 130 (2008), 2382–2383.
47. [47] Niedermayer, S., Weiss, V., Herrmann, A., Schmidt, A., Datz, S., Muller, K., Wagner, E., Bein, T., Brauchle, C., Multifunctional polymer-capped mesoporous silica nanoparticles for pH-responsive targeted drug delivery. Nanoscale 7 (2015), 7953–7964.
48. [48] Mackowiak, S.A., Schmidt, A., Weiss, V., Argyo, C., von Schirnding, C., Bein, T., Brauchle, C., Targeted drug delivery in cancer cells with red-light photoactivated mesoporous silica nanoparticles. Nano. Lett. 13 (2013), 2576–2583.
49. [49] Knezevic, N.Z., Lin, V.S., A magnetic mesoporous silica nanoparticle-based drug delivery system for photosensitive cooperative treatment of cancer with a mesopore-capping agent and mesopore-loaded drug. Nanoscale 5 (2013), 1544–1551.
50. [50] He, D., He, X., Wang, K., Cao, J., Zhao, Y., A light-responsive reversible molecule-gated system using thymine-modified mesoporous silica nanoparticles. Langmuir: ACS J. Surf. Coll. 28 (2012), 4003–4008.
51. [51] Thomas, C.R., Ferris Lee, D.P.J.-H., Choi, E., Cho, M.H., Kim, E.S., Stoddart, J.F., Shin, J.-S., Cheon, J., Zink, J.I., Noninvasive remote-controlled release of drug molecules in vitro using magnetic actuation of mechanized nanoparticles. J. Am. Chem. Soc. 132 (2010), 10623–10625.
52. [52] Mudgil, D., Barak, S., Khatkar, B.S., Guar gum: processing, properties and food applications—a review. J. Food Sci. Technol. 51 (2014), 409–418.
53. [53] Finley, J.W., Soto-Vaca, A., Heimbach, J., Rao, T.P., Juneja, L.R., Slavin, J., Fahey, G.C., Safety assessment caloric value of partially hydrolyzed guar gum. J. Agric. Food Chem. 61 (2013), 1756–1771.
54. [54] Tomlin, J., Read, N.W., Edwards, C.A., Duerden, B.I., The degradation of guar gum by faecal incubation system. Br. J. Nutr. 55 (1986), 481–486.
55. [55] Balascio, J.R., Palmer, J.K., Salyers, A.A., Degradation of guar gum by enzymes produced by a bacterium from the human colon. J. Food Biochem. 5 (1981), 271–282.
56. [56] Prabaharan, M., Prospective of guar gum and its derivatives as controlled drug delivery systems. Int. J. Biol. Macromol. 49 (2011), 117–124.
57. [57] Meng, H., Liong, M., Xia, T., Li, Z., Ji, Z., Zink, J.I., Nel, A.E., Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 4 (2010), 4539–4550.
58. [58] Lu, J., Liong, M., Zink, J.I., Tamanoi, F., Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 3 (2007), 1341–1346.
59. [59] Kung, K.-H.S., Hayes, K.F., Fourier transform infrared spectroscopic study of the adsorption of CetyltrimethylammoniumBromide and cetylpyridinium chloride on silica. Langmuir: ACS J. Surf. Colloids 9 (2016), 263–267.
60. [60] DeMuth, P., Hurley, M., Wu, C., Galanie, S., Zachariah, M.R., DeShong, P., Mesoscale porous silica as drug delivery vehicles: synthesis, characterization, and pH-sensitive release profiles. Microporous Mesoporous Mat. 141 (2011), 128–134.
61. [61] Kresge, C.T., Leonowicz, M.E., Roth, W.J., Vartuli, J.C., Beck, J.S., Ordered mesoporous molecular seives synthesised by a liquid-crystal template mechanism. Nature 359 (1992), 710–712.
62. [62] Trewyn, B.G., Slowing, I.I., Giri, S., Chen, H.-T., Lin, V.S.-Y., Synthesis and functionalization of a mesoporous silica nanoparticle based on the sol–gel process and applications in controlled release. Acc. Chem. Res. 40 (2007), 846–853.
63. [63] Papamichael, D., The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status. Oncologist 4 (1999), 478–487.
64. [64] Fu, Y., Yang, G., Zhu, F., Peng, C., Li, W., Li, H., Kim, H.-G., Bode, A.M., Dong, Z., Dong, Z., Antioxidants decrease the apoptotic effect of 5-Fu in colon cancer by regulating Src-dependent caspase-7 phosphorylation. Cell. Death. Dis. 5 (2014), 1–10.
65. [65] Wang, Q., Ellis, P.R., Murphy, S.B.R., The stability of guar gum in an aqueous system under acidic conditions. Food Hydrocolloids 14 (2000), 129–134.
66. [66] Akhdara, H., Loyerb, P., Raucha, C., Corlub, A., Guillouzoa, A., Morel, F., Involvement of Nrf2 activation in resistance to 5-fluorouracil in human colon cancer HT-29 cells. Eur. J. Cancer 45 (2009), 2219–2227.
67. [67] Sharma, R., Adam, E., Schumacher, U., The action of 5-fluorouracil on human HT29 colon cancer cells grown in SCID mice: mitosis, apoptosis and cell differentiation. Br. J. Cancer 76 (1997), 1011–1016.
68. [68] Camplejohn, R.S., Schultze, B., Maurer, W., In vivo cell synchrony in the L1210 mouse leukaemia studied with 5-fluorouracil or 5-fluorouracil followed by cold thymidine infusion. Br. J. Cancer. 35 (1977), 546–556.